Similar to our results, previous studies have also shown that SAC treatment of patients with Alzheimer's disease [47], stroke [40], several chronic liver diseases [32] and diabetes mellitus [48] significantly enhances Nrf2 protein levels. This evidence concerns the gene NFE2L2 and stroke disorder.